R-Methuleptin
Lipodystrophy
Floatz Rating
B62/100
Confidence
Indicative
Sponsor
University of Michigan
Modality
protein_peptide
Development Phase
Phase 2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
47High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT01679197CT.gov Clinical Protocol to Investigate the Efficacy of Recombinant Human Leptin (Metreleptin) in Nonalcoholic Steatohepatitis (NASH) or Nonalcoholic Fatty Liver Disease (NAFLD) Associated With Lipodystrophy | — | Completed | — | — | — |
NCT00025883CT.gov Leptin to Treat Lipodystrophy | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Lipodystrophy
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| R-Methuleptin (this asset) | University of Michigan | P2 | B · 62 |
| Efavirenz | Juan A. Arnaiz | P4 | A |
| Lamivudine | Thomas Benfield | P4 | BBB |
| Pravastatin | Kirby Institute | P4 | BBB |
| Retrovir | Kirby Institute | P4 | BBB |
| Abacavir | Kirby Institute | P4 | BBB |
| Nevirapine Anhydrous | Kirby Institute | P4 | BBB |
| Metformin | Hospital Civil de Guadalajara | P4 | BBB |
| Dolutegravir | Thomas Benfield | P4 | BBB |
+28 more in the Lipodystrophy cohort
Other indications for R-Methuleptin
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Metabolic Dysfunction-Associated Steatotic Liver Disease | — | P2 | BB · 67 |
| Metabolic Dysfunction-Associated Steatohepatitis | — | P2 | B · 62 |
| Familial Partial Lipodystrophy | — | P2 | B · 57 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. R-Methuleptin in Lipodystrophy. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/r-methuleptin-lipodystrophy
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →